ECSP11011076A - Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma - Google Patents

Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma

Info

Publication number
ECSP11011076A
ECSP11011076A EC2011011076A ECSP11011076A ECSP11011076A EC SP11011076 A ECSP11011076 A EC SP11011076A EC 2011011076 A EC2011011076 A EC 2011011076A EC SP11011076 A ECSP11011076 A EC SP11011076A EC SP11011076 A ECSP11011076 A EC SP11011076A
Authority
EC
Ecuador
Prior art keywords
quinuclidin
carboxamide
benzo
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
EC2011011076A
Other languages
English (en)
Inventor
Richard Chesworth
Gideon Shapiro
Gerhard Koenig
Original Assignee
En Vivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by En Vivo Pharmaceuticals Inc filed Critical En Vivo Pharmaceuticals Inc
Publication of ECSP11011076A publication Critical patent/ECSP11011076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se ha encontrado que la (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida tiene efectos procognitivos en humanos en dosis inesperadamente bajas. Así, la (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sus sales farmacéuticamente aceptables pueden usarse en dosis inesperadamente bajas para mejorar la cognición
EC2011011076A 2008-11-19 2011-05-23 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma ECSP11011076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11610608P 2008-11-19 2008-11-19
PCT/US2009/065173 WO2010059844A1 (en) 2008-11-19 2009-11-19 Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
ECSP11011076A true ECSP11011076A (es) 2011-09-30

Family

ID=41786120

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011076A ECSP11011076A (es) 2008-11-19 2011-05-23 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma

Country Status (34)

Country Link
US (6) US8642638B2 (es)
EP (4) EP2355822B1 (es)
JP (6) JP5272080B2 (es)
KR (3) KR20180011888A (es)
CN (3) CN105687190A (es)
AU (1) AU2009316557B2 (es)
BR (1) BRPI0922057A2 (es)
CA (3) CA3017886A1 (es)
CL (3) CL2011001178A1 (es)
CO (1) CO6400190A2 (es)
CR (1) CR20110267A (es)
CY (3) CY1113671T1 (es)
DK (3) DK2540297T3 (es)
EC (1) ECSP11011076A (es)
ES (3) ES2673016T3 (es)
HR (3) HRP20130007T1 (es)
HU (2) HUE037938T2 (es)
IL (5) IL212921A (es)
LT (1) LT2889033T (es)
MX (1) MX2011005270A (es)
MY (2) MY173229A (es)
NZ (2) NZ613291A (es)
PE (1) PE20110711A1 (es)
PH (2) PH12014501629B1 (es)
PL (3) PL2540297T3 (es)
PT (3) PT2889033T (es)
RS (1) RS52583B (es)
RU (3) RU2532327C2 (es)
SG (1) SG10201504102QA (es)
SI (3) SI2889033T1 (es)
SM (3) SMT201800308T1 (es)
TR (1) TR201807944T4 (es)
WO (1) WO2010059844A1 (es)
ZA (1) ZA201104044B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
US20130231365A1 (en) * 2010-11-18 2013-09-05 Gerhard Koenig Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors
EP2706854A4 (en) * 2011-05-09 2014-12-03 Envivo Pharmaceuticals Inc TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE
AU2012279298A1 (en) * 2011-07-01 2014-01-23 Envivo Pharmaceuticals, Inc. Methods of treatment of Limited Cognitive Impairment
EP3461481A1 (en) * 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JP7170670B2 (ja) 2017-02-27 2022-11-14 ユニヴァーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイアー エデュケイション 抗精神病組成物及び治療方法
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3849410A4 (en) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC SYSTEM AND METHODS FOR ENHANCEMENT OF SLEEP

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (de) 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de) 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
US4985420A (en) 1987-12-10 1991-01-15 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and -amides
US5198437A (en) 1987-12-10 1993-03-30 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and amides
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en) 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5114947A (en) 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de) 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
JP3708962B2 (ja) 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
FR2756826B1 (fr) 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EE04057B1 (et) 1997-05-30 2003-06-16 Neurosearch A/S 8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
CA2343320A1 (en) 1998-09-18 2000-03-30 The Rockefeller University Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en) 1999-11-08 2002-07-09 Research Triangle Institute Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
JP2003530542A (ja) 1999-12-01 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経変性疾患の診断方法
AU784644B2 (en) 1999-12-14 2006-05-18 Pharmacia & Upjohn Company Human ion channels
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
TR200402656T4 (tr) 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr) 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10044905A1 (de) 2000-09-12 2002-03-21 Merck Patent Gmbh (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
ES2275808T3 (es) 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
CA2455773A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
JP2003081978A (ja) 2001-09-10 2003-03-19 Mitsubishi Pharma Corp スピロ環式化合物およびその医薬用途
BR0212477A (pt) 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
MXPA04003007A (es) 2001-10-02 2004-07-15 Upjohn Co Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
WO2003037896A1 (en) 2001-10-26 2003-05-08 Pharmacia & Upjohn Company N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
MXPA04004464A (es) 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
WO2003042210A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
FR2832714B1 (fr) 2001-11-23 2004-07-16 Sanofi Synthelabo Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
PL374384A1 (en) 2001-12-14 2005-10-17 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10162442A1 (de) 2001-12-19 2003-07-03 Bayer Ag Monocyclische N-Aryl-amide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10164139A1 (de) * 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
WO2003070731A2 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2003070732A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1478646A1 (en) 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1502110A4 (en) 2002-05-09 2007-09-05 Memory Pharm Corp MUTANT CELL SURFACE EXPRESSED CANAL RECEPTORS TRANSFECTED QM-7 AND QT-6 CELLS AND TRANSFIED CELLS USING TESTS
CA2495432A1 (en) 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
BR0313460A (pt) 2002-08-13 2005-07-05 Warner Lambert Co Derivados de naftaleno como inibidores de metaloproteinase da matriz
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
MXPA05005666A (es) 2002-12-11 2005-07-26 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con combinaciones de agonistas del receptor nicotinico de acetilcolina alfa-7 y otros compuestos.
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1611128A2 (en) 2003-03-28 2006-01-04 Pharmacia & Upjohn Company LLC Positive allosteric modulators of the nicotinic acetylcholine receptor
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
CA2551486A1 (en) 2003-12-22 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
CA2560741C (en) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
DK2152712T3 (da) 2007-05-11 2012-03-26 Pfizer Aminoheterocykliske fobindelser
CA2694401C (en) 2007-08-31 2012-12-04 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
DE602008005928D1 (de) 2007-10-01 2011-05-12 Comentis Inc 1h-indol-3-carbonsäure-chinuclidin-4-ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
WO2009067579A1 (en) 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
JP5721230B2 (ja) 2008-04-29 2015-05-20 ファーネクストＰｈａｒｎｅｘｔ 血管新生の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ
EP2282779B1 (en) 2008-04-29 2013-03-13 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
WO2009133128A1 (en) 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
EP2381955A4 (en) 2008-12-30 2013-01-16 Univ Ramot COMBINATION THERAPIES WITH NAP
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
PL3395372T3 (pl) 2009-02-20 2022-07-25 EnhanX Biopharm Inc. Układ do dostarczania leków na bazie glutationu
AU2010218714A1 (en) 2009-02-26 2011-09-08 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012523437A (ja) 2009-04-13 2012-10-04 セラヴァンス， インコーポレーテッド 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物
CA2764387A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions

Also Published As

Publication number Publication date
NZ593467A (en) 2013-07-26
PT2355822E (pt) 2013-01-14
SMT201800308T1 (it) 2018-09-13
KR20140146216A (ko) 2014-12-24
HUE037938T2 (hu) 2018-09-28
PH12018500023A1 (en) 2019-07-15
IL256313A (en) 2018-02-28
CA3017886A1 (en) 2010-05-27
PL2355822T3 (pl) 2013-03-29
JP2013166771A (ja) 2013-08-29
CY1116460T1 (el) 2017-03-15
RU2014122858A (ru) 2015-12-10
US20130137717A1 (en) 2013-05-30
RU2011124515A (ru) 2012-12-27
HRP20150711T1 (hr) 2015-08-14
EP2889033B1 (en) 2018-03-21
IL212921A0 (en) 2011-07-31
LT2889033T (lt) 2018-07-10
JP2018039818A (ja) 2018-03-15
IL256140A (en) 2018-02-28
EP3357495A1 (en) 2018-08-08
NZ613291A (en) 2014-11-28
DK2889033T3 (en) 2018-07-02
IL242034A (en) 2017-12-31
RU2018125456A (ru) 2020-01-13
IL242034A0 (en) 2015-11-30
KR20110091549A (ko) 2011-08-11
US20140155430A1 (en) 2014-06-05
JP2016128442A (ja) 2016-07-14
CN105687190A (zh) 2016-06-22
US20180271844A1 (en) 2018-09-27
DK2540297T3 (en) 2015-07-13
US8642638B2 (en) 2014-02-04
CA2894860A1 (en) 2010-05-27
KR20180011888A (ko) 2018-02-02
US8815933B2 (en) 2014-08-26
CY1113671T1 (el) 2016-07-27
RU2532327C2 (ru) 2014-11-10
JP5869653B2 (ja) 2016-02-24
EP2540297B1 (en) 2015-04-08
PL2889033T3 (pl) 2018-10-31
US8569354B2 (en) 2013-10-29
IL212921A (en) 2015-11-30
CN102281878A (zh) 2011-12-14
HRP20130007T1 (hr) 2013-01-31
PH12014501629A1 (en) 2016-01-18
SG10201504102QA (en) 2015-06-29
CR20110267A (es) 2011-10-13
EP3357495B1 (en) 2019-12-25
ES2541528T3 (es) 2015-07-21
CA2744278C (en) 2015-09-08
AU2009316557B2 (en) 2015-08-27
TR201807944T4 (tr) 2018-06-21
EP2355822A1 (en) 2011-08-17
HUE026815T2 (en) 2016-07-28
RU2662560C2 (ru) 2018-07-26
PE20110711A1 (es) 2011-10-11
BRPI0922057A2 (pt) 2015-12-15
SMT201500167B (it) 2015-09-07
US20150265583A1 (en) 2015-09-24
PT2540297E (pt) 2015-08-26
EP2889033A1 (en) 2015-07-01
CL2011001178A1 (es) 2011-10-14
MY159826A (en) 2017-02-15
JP5272080B2 (ja) 2013-08-28
CY1121607T1 (el) 2020-05-29
SMT201300003B (it) 2013-05-06
PL2540297T3 (pl) 2015-12-31
CA2894860C (en) 2018-11-06
PH12014501629B1 (en) 2016-01-18
AU2009316557A1 (en) 2010-05-27
CA2744278A1 (en) 2010-05-27
WO2010059844A1 (en) 2010-05-27
MY173229A (en) 2020-01-07
EP2540297A1 (en) 2013-01-02
US20140148479A1 (en) 2014-05-29
HK1158520A1 (en) 2012-07-20
ZA201104044B (en) 2012-11-28
SI2540297T1 (sl) 2015-08-31
CL2018001420A1 (es) 2018-09-28
JP2012509347A (ja) 2012-04-19
ES2673016T3 (es) 2018-06-19
US20110288119A1 (en) 2011-11-24
JP2020040977A (ja) 2020-03-19
SI2889033T1 (en) 2018-08-31
RS52583B (sr) 2013-04-30
EP2355822B1 (en) 2012-10-10
ES2396300T3 (es) 2013-02-20
PT2889033T (pt) 2018-06-18
JP2015083574A (ja) 2015-04-30
DK2355822T3 (da) 2013-01-28
IL242035A0 (en) 2015-11-30
HRP20180942T1 (hr) 2018-08-10
JP6223480B2 (ja) 2017-11-01
JP5674854B2 (ja) 2015-02-25
CN105687191A (zh) 2016-06-22
MX2011005270A (es) 2011-08-03
CO6400190A2 (es) 2012-03-15
SI2355822T1 (sl) 2013-02-28
CL2017001853A1 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
ECSP11011076A (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
AR084051A1 (es) Derivados de 1-hidroxi-2-oxo-hidroquinolina, composiciones farmaceuticas que los contienen y uso de los mismos para tratar deficits cognitivos asociados con esquizofrenia y otros trastornos psiquiatricos y/o neurologicos